Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma

Medical Oncology

Volumn 22, Issue 2, 2005, Pages 203-206

  Kurt, Mevlut ^a   Onal, Ibrahim K ^a   Elkiran, Tamer ^a   Altun, Bulent ^a   Altundag, Kadri ^a,b   Gullu, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (United States)

Author keywords

Antitumor potential; Tumor lysis syndrome; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER CYTODIAGNOSIS; CANCER MORTALITY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; GENERAL CONDITION DETERIORATION; HUMAN; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG METASTASIS; MALE; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME;

ACUTE DISEASE; ADENOCARCINOMA; DIPHOSPHONATES; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 22344454772     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:2:203     Document Type: Article

References (19)

1. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997;103:363-367.
2. Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 1993;21:521-524.
3. Woo IS, et al. Spontaneous acute tumor lysis syndrome with advanced gastric cancer. J Korean Med Sci 2001;16:115-118.
4. Feld J, Mehta H, Burkes RL. Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report. Am J Clin Oncol 2000;23:491-493.
5. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187-192.
6. Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am J Med Sci 2003;325:38-40.
7. Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol 1995;18:71-73.
8. Beriwal S, Singh S, Garcia-Young JA. Tumor lysis syndrome in extensive-stage small-cell lung cancer. Am J Clin Oncol 2002;25:474-475.
9. Sewani HH, Rabatin JT. Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor. Mayo Clin Proc 2002;77:722-728.
10. Kallab AM, Jillella AP. Tumor lysis syndrome in small cell lung cancer. Med Oncol 2001;18:149-151.
11. Rosen LS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
12. Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol 2002;29(6 Suppl 21): 3-11.
13. Kimura S, et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004;79:37-43.
14. Ural AU, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003;78:443-449.
15. Tassone P, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-844.
16. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004;94:164-170.
17. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221.
18. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468.
19. Tassone P, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003;88:1971-1978.